1 / 23

New users of benzodiazepines: implications for elder patient safety

New users of benzodiazepines: implications for elder patient safety. G. Bartlett, PhD Family Medicine McGill University. Outline. Benzodiazepine use in the elderly Objectives of study Methods Population & data sources Results – new users vs non-users Results – predictors of new use

borna
Download Presentation

New users of benzodiazepines: implications for elder patient safety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. New users of benzodiazepines: implications for elder patient safety G. Bartlett, PhD Family Medicine McGill University

  2. Outline • Benzodiazepine use in the elderly • Objectives of study • Methods • Population & data sources • Results – new users vs non-users • Results – predictors of new use • Conclusions, Limitations • Future Directions

  3. Benzodiazepines - review • Sedative/hypnotics: • hypnotic, anxiolytic, anticonvulsant, muscular relaxant, amnesic • high efficacy, rapid onset of action, low toxicity • unique among psychotropics for multiple indications and relative safety compared with other sedative/hypnotics

  4. Concerns about Benzodiazepines • psychomotor impairment • paradoxical excitement • tolerance, dependence and withdrawal effects with long term use • injuries from falls

  5. Concerns about Benzodiazepinesfor the Elderly Due to changes that occur with normal aging, elderly demonstrate increased sensitivity to: • psychomotor impairment • memory impairment • rebound or withdrawal effects • interactions with other medications/conditions

  6. Use of Benzodiazepines:Why the Elderly? • insomnia can be a “pathological” feature associated with age • anxiety due to other illnesses • more likely to suffer acute grief reactions • fewer complications with benzodiazepines than with tricyclic anti-depressants and anti-psychotics

  7. Why are we still discussing benzodiazepine safety? • Risk from injuries from falls for benzodiazepines still in dispute • Physicians may be prescribing benzodiazepines perceived to be safer to higher risk patients • Pre-existing risk factors may be cause confounding in published studies What risk factors for falls are present before a benzodiazepine is prescribed?

  8. Methods • All patients >65 years with no benzodiazepine script in baseline year • Risk factors for falls assessed in baseline year: • age & sex • clinical characteristics • disabilities & impairments • prior hospitalizations • prior health care use • use of other prescription medication. • 5 years of follow-up until first benzodiazepine script dispensed – product name identified

  9. Benzodiazepines available in QC • Triazolam (Halcion) • Midazolam (Versed) – IV only • Alprazolam (Xanax) • Bromazepam (Lectopam) • Lorazepam (Ativan) • Oxazepam (Serax) • Nitrazepam (Mogadon) • Temazepam (Restoril) • Clobazam (Frisium) • Clonazepam (Rivotril) • Diazepam (Valium) • Flurazepam (Dalmane) • Chlordiazepoxide (Librium) • Clorazepate* (Traxene)

  10. Data Sources: The Quebec Health Care Databases • Beneficiary Database: all Quebec residents, age, sex, date of death, address • Pharmaceutical Database: all claims for prescriptions dispensed to elderly and welfare recipients in Quebec • Medical Services Claims: all medical services provided on a fee-for-service basis (90%) to Quebec residents • Hospitalization Database: all discharges from Quebec hospitals - dates for hospitalization

  11. Study Sample

  12. Study Overview Baseline Follow-up Jan. 1989 Jan. 1990 Dec. 1994

  13. Results - general • average age 73.4 years with 52% women • 78,367 (31%) new benzodiazepine users • New users had an almost two-fold increase in use of anti-depressants and sedatives, cardiac medications, anti-hypertensive agents, vasodilators and diuretics • 9.5% of new users versus 5.6% of non-users filled at least one prescription for another psychotropic medication • 44% of new users vs 38% of non-users filled at least one prescription for medications that affect motor stability • New users were more likely to have depression and arthritis, and used more health care services than non-users

  14. Results – product specific • decreased risk of starting oxazepam and flurazepam for older ages • women were more to be new users of the majority of the benzodiazepines except temazepam and flurazepam • each additional prescribing physician seen increased by risk of new use by 5-15% • having an fall injury decreased risk for lorazepam (HR=0.93, p=0.01) and diazepam (HR=0.86, p=0.04) and an increased probability for chlordiazepoxide (HR=1.34, p=0.04)

  15. Results – disabilities and impairments • depression was strongly associated with new use except triazolam and temazepam -particularly strong for alprazolam (HR=1.98, p<0.0001) and clonazepam (HR=2.46, p<0.0001) • weaker but consistently positive increased risk for arthritis • neurological disorders (including dementia and Parkinson’s disease) and clonazepam (HR=2.24, p<0.0001); • alcohol abuse and both oxazepam (HR=1.55 p=0.001) and chlordiazepoxide (HR=12.1, p<0.0001) • drug abuse with bromazepam (HR=2.34, p=0.0008).

  16. Results – disabilities and impairments • strongest and most consistent associations were seen for use of anti-depressants as well as other psychotropic medications (anti-psychotics and non-benzodiazepine sedatives, lithium or l-tryptophan) • filling a prescription for an anti-depressant significantly increased risk varying from a 23% increase for diazepam (HR=1.23) to more than tripling the hazard for clonazepam (HR=3.13) • use of anti-psychotics, other sedatives, and lithium or l-tryptophan increased risk by more than double for new clonazepam and flurazepam use and over five times for clonazepam (HR=5.19, p<0.0001).

  17. Conclusions • Factors associated with new benzodiazepine use vary considerably among the individual products • Physicians appear to be “channeling” new users based on own criteria – not necessarily evidence based • Any research on risk needs to account for these factors by individual products

  18. Limitations • under-diagnosis and under-reporting of the treatment of certain diseases • anxiety and insomnia were often not coded in the database making it difficult to assess the association between these diagnoses and benzodiazepine use • proxy measure of use (dispensed prescription) • no prescription information available during hospitalization

  19. Future Directions • Why benzodiazepines are chosen by physicians – are other risk factors accounted for? • Role of risk in guidelines recommendations… • Methods to reduce risk of falls – smart alerts? • Investigations of risk from falls – are other risk factors accounted for? • Is dose adjusted for in high risk patients?

  20. Questions & Comments gillian.bartlett@mcgill.ca

More Related